

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
PC25572A

In Re Application Of: **Bell, et al**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/580,306	May 24, 2006	Not Assigned	26648	Not Assigned	Not Assigned

Re: **OPYRAZOLOPYRIMIDINES**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Information Disclosure Statement, IDS Form 1449, Copies of References (67), and Return Postcard

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Rachel A. Polster

Signature

Rachel A. Polster
47,004

Dated: **July 26, 2006**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 26, 2006

(Date)

Linda Haley

Signature of Person Mailing Correspondence

Linda Haley

Typed or Printed Name of Person Mailing Correspondence

CC:



PATENT

PC25572A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Bell, et al

SERIAL NO: 10/580,306

FILED: May 24, 2006

)

)

)

)

)

)

GROUP ART UNIT: Not Assigned

EXAMINER: Not Assigned

DATE: July 26, 2006

TITLE: PYRAZOLOPYRIMIDINES

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please note that we are submitting English language equivalents for:

B22. WO9924433(A1) – (US6,566,360 B1) **B23.** WO 01/18004 – (US 6,777,419)

B24. DE 10104095 – (US 2004/0077664 A1) **B25.** WO 200241880 – (US 2004/0023990 A1)

B26. WO 200249651 – (US 2004/0063730 A1) **B27.** WO 02/00660 – (US 2004/0029900 A1)

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

Rachel A. Polster

Registration No.47,004

(314) 274-7354 (St. Louis)

Pharmacia Corporation

Global Patent Department

P. O. Box 1027

St. Louis, MO 63006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: PC25572A	APPLICATION NO.: 10/580,306
	INVENTOR : Bell, et al.	
	Filed: May 24, 2006	Group: Not Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	6465486	October 15, 2002	Baxter et al.	31	47	March 10, 2000
	A2	4282361	August 11, 1981	Uehara et al.	13	02	April 2, 1979
	A3	3951980	April 20, 1976	Henry et al.	451	02	August 21, 1975
	A4	5442044	Aug 15, 1995	Hoover et al.	5	06	March 8, 1993
	A5	3951980	April 20, 1976	Henry et al.	451	02	August 21, 1975
	A6	6432957	August 13, 2002	Kodoma et al.	31	496	June 29, 2001
	A7	2004/0029900	January 1, 2004	Sander et al.	17	30	June 28, 2002
	A8	6184338	February 6, 2001	Schwindeman, et. al.	528	392	August 24, 1998
	A9	2002/0127593	September 12, 2002	Reich, et. al.	435	6	March 8, 2002
	A10	6288078	September 11, 2001	Walsh, et. al.	514	300	March 7, 2000
	A11	2002/0058668	May 16, 2002	Jun Yuan	514	258	March 23, 2001
	A12	2003/0187261	October 2, 2003	Havlicek, et. al.	514	276	January 8, 2001
	A13	5091431	February 25, 1992	Tulshian, et. al.	514	262	February 6, 1989
	A14	6106864	August 22, 2000	Dolan, et. al.	9	14	August 21, 1996
	A15	2001/0047013	November 29, 2001	Lang, et. al.	213	02	March 5, 2001
	A16	6001830	December 14, 1999	Lee, et. al.	31	50	November 12, 1998
	A17	6130223	October 10, 2000	Jonas, et. al.	514	258	October 8, 1997
	A18	6566360	May 20, 2003	Niewohner, et. al.	514	243	August 30, 2001
	A19	6777419	August 17, 2004	Jonas, et. al.	514	262.1	September 6, 1999
	A20	2004/0023990	February 5, 2004	Eggenweiler, et. al.	514	262.1	November 25, 2000
	A21	2004/0063730	April 1, 2004	Eggenweiler, et. al.	514	262.1	December 19, 2000
	A22	2004/0029900	February 12, 2004	Jonas, et. al.	514	262.1	June 29, 2000

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO 93/06104	April 1, 1993	PCT	487	04	X	
	B2	WO 00/24745	May 4, 2000	PCT	487	04	X	
	B3	WO 01/27112	April, 19, 2001	PCT	487	04	X	
	B4	WO 01/27113	April 19, 2001	PCT	487	04	X	
	B5	WO 93/07149	April 15, 1993	PCT	487	04	X	
	B6	WO 93/12095	June 24, 1993	PCT	239	91	X	
	B7	WO 94/05661	March 17, 1994	PCT	471	04	X	
	B8	WO 94/00453	January 6, 1994	PCT	473	30	X	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: PC25572A	APPLICATION NO.: 10/580,306
	INVENTOR : Bell, et al	
	Filed: May 24, 2006	Group: Not Assigned

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B9	WO 95/19978	July 27, 1995	PCT	471	14	X	
	B10	WO 98/49166	November 5, 1998	PCT	487	04	X	
	B11	WO 01/32646	May 10, 2001	PCT	401	00	X	
	B12	WO 01/47901	July 5, 2001	PCT	271	06	X	
	B13	WO 02/42292	May 30, 2002	PCT	401	06	X	
	B14	WO 99/45006	September 10, 1999	PCT	413	14	X	
	B15	EP 1176142	January 30, 2002	EP	231	14	X	
	B16	WO 02/10171	February 7, 2002	PCT	487	04	X	
	B17	EP 1072595	January 31, 2001	EP	211	22	X	
	B18	EP 319479	June 7, 1989	EP	9	30	X	
	B19	EP0296811	June 25, 1987	EP	125	067	X	
	B20	EP0297858	July 2, 1987	EP	471	08	X	
	B21	EP 1241170	September 18, 2002	EP	487	14	X	
	B22	FR 2638745	November 8, 1988	FR	281	02		X
	B23	WO 04006867	March 13, 2003	PCT			X	
	B24	EP 0937459	August 25, 1999	EP	31	40	X	
	B25	JP 03142277	October 30, 1989	JP				X
	B26	EP 1348707	October 1, 2003	EP	487	04	X	
	B27	WO 8605519	September 25, 1986	PCT	1	68	X	
	B28	WO 8605518	September 25, 1986	PCT	1	68	X	
	B29	WO 0123389	April 5, 2001	PCT	487	04	X	
	B30	WO 0213798	February 21, 2002	PCT	31	00	X	
	B31	WO 9954333	October 28, 1999	PCT	487	04	X	
	B32	WO 9301181	January 21, 1993	PCT	401	12	X	
	B33	JP 2002255932	September 11, 2002	JP	205	04		X
	B34	EP 400661	May 31, 1990	EP	403	04	X	
	B35	WO 02102314	December 27, 2002	PCT			X	
	B36	EP 1176147	January 30, 2002	EP	487	04	X	
	B37	WO 2004096810	November 11, 2004	PCT	487	04	X	
	B38	WO 0147495	July 5, 2001	PCT	9	14	X	
	B39	WO 02066481	August 29, 2002	PCT	487	04	X	
	B40	WO 9928325	June 10, 1999	PCT	495	04		X
	B41	WO 9817668	April 30, 1998	PCT	495	04		X
	B42	EP 0579496	November 14, 2001	EP	401	04	X	
	B43	WO 9616657	June 6, 1996	PCT	31	505	X	
	B44	EP 0349239	July 1, 1988	EP	487	04	X	
	B45	DE 10104095	January 31, 2001	Germany	31	519		X

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: PC25572A	APPLICATION NO.: 10/580,306
	INVENTOR : Bell, et al	
	Filed: May 24, 2006	Group: Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Organic Reactions, Volume 41 and Volume 42, page 42, 1992
	C2	Chambers et al. Journal Organic Chemistry, <i>Selective Sequential Demasking of the Ester Functions of 1-Methyl-3,4,5-tris(methoxycarbonyl) pyrazole</i> , 50, 4736-4738, 1985
	C3	Zeitschrift fur Chemie 28; 2; 59-60, 1988
	C4	Webber, R., et.al., Journal Med. Chem., <i>Substituted 2-Iminopiperidines as Inhibitors of Human Nitric Oxide Synthase Isoforms</i> , 41 (1); 96-101, 1998
	C5	Singh, B., et. al., J Het. Chem., <i>Three Convenient and Novel Syntheses of 4-Amino-2-arylpyrimidines</i> , 14; 1413; 1977
	C6	Hara, H., et. al., J. Het. Chem., <i>On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group (1)</i> , 19; 1285; 1982
	C7	Orozco, M., et. al., J. Pharmaceutical Science, <i>Quantum Chemical Study of the Electronic and Conformational Characteristics of Adenosine and 8-Substituted Derivatives: Functional Implications in the Mechanism of Reaction of Adenosine Deaminase</i> , 79(2), 133-137, 1990
	C8	Orozco, M., et. a., Quantitative Struct.-Act. Relat., <i>Theoretical Approximation to the Reaction Mechanism of Adenosine Deaminase</i> , 8: 109-114, 1989
	C9	Orozco, M., et. al., Molecular Pharmacology, <i>Theoretical Study of the Protonation and Tautomerization of Adenosine, Formycin, and Their 2-NH₂ and 2-F Derivatives: Functional Implications in the Mechanism of Reaction of Adenosine Deaminase</i> , 35(2): 257-264, 1988
	C10	Upadhy, K., et. al., Nucleic Acids Research, <i>Synthesis of 5-chloroformycin A, 5-chloro-2'-deoxyformycin A and certain related 5,7-disubstituted 3-β-D-ribofuranosylpyrazolo[4,3-d]pyrimidines from formycin A</i> , 14(4): 1747-1764, 1986
	C11	Secrist III, J., et. al., Journal Med. Chem., <i>2-Fluoroformycin and 2-Aminoformycin. Synthesis and Biological Activity</i> , 28(11): 1740-1742, 1985
	C12	Diederich, F., <i>Metal-Catalysed Cross-Coupling Reactions</i> , Wiley-VCH, 1998
	C13	Norris, T., et. al., J. Chem. Soc. Perkin Trans. 1, <i>Synthesis of trovafloxacin using various (1α,5α,6α)-3-azabicyclo[3.1.0]hexane derivatives</i> , 1615-1622, 2000
	C14	Bochis, R., et. al., J. Med. Chem., <i>Substituted Imidazo[1,2-a]pyridine-2-carbamate Anthelmintics</i> , 24(12) 1518-1521, 1981
	C15	Yakovlev, M., et. a., Chemistry of. Heterocyclic Compound, <i>Synthesis of Substituted 2,5-Diazabicyclo[2.2.1]Heptanes</i> , 36(4): 429-431, 2000

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: PC25572A	APPLICATION NO.: 10/580,306
	INVENTOR : Bell, et al	
	Filed: May 24, 2006	Group: Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C16	Smith, S., et. al., Tetrahedron Letters, <i>Tandem cyclisation and [2,3]-Stevens rearrangement to 2-substituted pyrrolidines</i> , 43, 899-902, 2002
	C17	Barlocco, D., et. al., J. Med. Chem., <i>Mono- and Disubstituted-3,8-diazabicyclo[3.2.1]octane Derivatives as Analgesics Structurally Related to Epibatidine: Synthesis, Activity, and Modeling</i> , 41, 674-681, 1998
	C18	Baraldi, P., et. al., IL Farmaco, <i>Synthesis, Antibacterial Activity and Structure-Activity Relationships of N-Substituted 4-Diazo-Pyrazole-5-Carboxamides</i> , 46 (11), 1337-1350, 1991
	C19	Brown, H., et. al., J. Org. Chem., <i>Hydroboration. 71. Hydroboration of Representative Heterocyclic Olefins with Borane-Methyl Sulfide, 9-Borabicyclo[3.3.1]nonane, Dicyclohexylborane, and Disiamylborane. Synthesis of Heterocyclic Alcohols</i> , 50, 1582-1589, 1985
	C20	H.C. Van Der Plas, Rec.l. Trav. Chim. Pays-Bas., <i>Syntheses of Amino and Bromo Derivatives of 4-methyl-, 4-t-butyl- and 4-phenyl-pyrimidine</i> , 84, 1101-1106, 1965
	C21	Dumaitre, B., et. al., Journal of Medicinal Chemistry, American Chemical Society, <i>Synthesis and Cyclic GMP Phosphodiesterase Inhibitory Activity of a Series of 6-Phenylpyrazolou3, 4-Dpyrimidones</i> , 39(8), 1635-1644, 1996
	C22	Czarniecki, M., et. al., Annu. Rep. Med. Chem., <i>Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy</i> , 31, 61-70, 1996

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	